vidually indicated to be incorporated by reference. In case of conflict, the present application, including any definitions herein, will control.

EQUIVALENTS

[0465] While specific aspects and embodiments of the subject disclosure have been discussed, the above specification is illustrative and not restrictive. Many variations of the disclosure will become apparent to those skilled in the art upon review of this specification and the claims below. The full scope of the disclosure should be determined by reference to the claims, along with their full scope of equivalents, and the specification, along with such variations.

What is claimed is:

1. A pharmaceutically effective non-aqueous composition comprising particles:

wherein a plurality of the particles in the composition are suspended in an organic solvent carrier and comprise at least one antibody or a fragment thereof, wherein each particle that comprises at least one antibody or a fragment thereof has greater than about 70% antibody or fragment thereof by weight;

wherein:

the particles have less than about 3% aggregation of the antibody or fragment thereof; and

the concentration of the antibody or fragment thereof in the composition is from about 400 mg/mL to about 650 mg/mL.

2. The composition of claim **1**, wherein the particles have less than about 3% change in charge variants of the antibody or fragment thereof.

3. The composition of claim **1**, wherein the particles have a circularity from about 0.80 to about 1.00.

4. The composition of claim **1**, wherein the particles have less than about 3% residual moisture by weight.

5. The composition of claim **1**, wherein each particle has less than about 10% internal void space.

6. The composition of claim **1**, wherein each particle has less than about 5% internal void space.

7. The composition of claim **1**, wherein each particle has less than about 1% internal void space.

8. The composition of claim **1**, wherein each particle is free from any internal void space.

9. The composition of claim **1**, wherein the particles have greater than about 70% antibody or fragment thereof by weight.

10. The composition of claim **1**, wherein the particles have greater than about 80% antibody or fragment thereof by weight.

11. The composition of claim **1**, wherein the particles further comprise a carbohydrate, a pH adjusting agent, a salt, a chelator, a mineral, a polymer, a surfactant, a protein stabilizer, an emulsifier, an antiseptic, an amino acid, an antioxidant, a protein, an organic solvent, a paraben, a bactericide, a fungicide, a vitamin, a preservative, a nutrient media, analgesic, or a combination thereof.

12. The composition of claim **1**, wherein the composition has a viscosity of less than about 100 mPa·s.

13. The composition of claim **1**, wherein the composition is free of insoluble Subvisible Particles (SvPs) upon dissolution in water.

14. The composition of claim **1**, wherein the composition upon dissolution in water has a turbidity that differs from the turbidity of an aqueous composition comprising the antibody or a fragment thereof, by less than 0.1 FTU.

15. The composition of claim **1**, wherein the composition has no change in immunogenicity compared to an aqueous composition comprising the antibody or fragment thereof.

16. The composition of claim **1**, wherein the composition is non-immunogenic.

17. The composition of claim **1**, wherein the composition has no change in toxicity compared to an aqueous composition comprising the antibody or fragment thereof.

18. The composition of claim **1**, wherein the composition is non-toxic.

19. The composition of claim **1**, wherein the antibody or fragment thereof in the composition is stable for at least three months.

20. The composition of claim **1**, wherein the antibody or fragment thereof in the composition is stable for at least three months at 40° C.

* * * * *